About
Small Molecules acting to degrade proteins
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
8
As Collaborator
2
Total Enrollment
1,003
By Phase
PHASE2: 3PHASE1: 6
By Status
COMPLETED: 6ACTIVE_NOT_RECRUITING: 3RECRUITING: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT07217015Lead Sponsor
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
PHASE2Recruiting
200 participants
Started: Nov 30, 2025 · Completed: Jun 30, 2028
NCT06945458Lead Sponsor
Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)
PHASE1Active, not recruiting
20 participants
Started: Apr 17, 2025 · Completed: Dec 31, 2025
NCT06673667Lead Sponsor
First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants
PHASE1Completed
118 participants
Started: Oct 22, 2024 · Completed: Apr 23, 2025
NCT06058156Collaborator
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
PHASE2Active, not recruiting
200 participants
Started: Nov 9, 2023 · Completed: Aug 18, 2026
NCT06028230Collaborator
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
PHASE2Active, not recruiting
156 participants
Started: Sep 29, 2023 · Completed: Jul 17, 2026
Locations (1)
Headquarters
Watertown, MA, United States
Map
Loading map...